This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Refractive Surgery  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Ophthalmol. 2005;123:109-113.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Topical mitomycin C (MMC) is effective for treatment of superficial or invasive squamous cell carcinoma (SCC) of the conjunctiva.^1-11 In most instances, the chemotherapy agent is delivered 4 times daily in topical eyedrop form directly on the affected ocular surface. The medication is continued generally for 3 or 4 weeks, at which time the tumor is usually completely regressed.

Published results have shown that thin tumors, typically those that are less than 4 mm in thickness, show complete regression with MMC.^1-8 Complete regression can be found with thin tumors even if they are extensive over most of the conjunctival and corneal surface.⁸ Thick tumors (4 mm in thickness), however, may show only partial regression with MMC, and there is the temptation to continue the medication for a prolonged period. Nevertheless, some patients do not show a complete response despite several chemotherapy cycles, and in such cases, prolonged therapy with . . . [Full Text of this Article]

Report of Cases

Case 1

Case 2

Case 3

Comment

AUTHOR INFORMATION
Carol L. Shields, MD; Hakan Demirci, MD; Brian P. Marr, MD; Arman Masheyekhi, MD; Miguel Materin, MD; Jerry A. Shields, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?